Literature DB >> 25538088

Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood.

Veerle Melotte1, Joo Mi Yi2, Marjolein H F M Lentjes1, Kim M Smits3, Leander Van Neste4, Hanneke E C Niessen1, Kim A D Wouters1, Joost Louwagie5, Kornel E Schuebel6, James G Herman6, Stephen B Baylin6, Wim van Criekinge5, Gerrit A Meijer7, Nita Ahuja8, Manon van Engeland9.   

Abstract

Identifying biomarkers in body fluids may improve the noninvasive detection of colorectal cancer. Previously, we identified N-Myc downstream-regulated gene 4 (NDRG4) and GATA binding protein 5 (GATA5) methylation as promising biomarkers for colorectal cancer in stool DNA. Here, we examined the utility of NDRG4, GATA5, and two additional markers [Forkhead box protein E1 (FOXE1) and spectrin repeat containing nuclear envelope 1 (SYNE1)] promoter methylation as biomarkers in plasma DNA. Quantitative methylation-specific PCR was performed on plasma DNA from 220 patients with colorectal cancer and 684 noncancer controls, divided in a training set and a test set. Receiver operating characteristic analysis was performed to measure the area under the curve of GATA5, NDRG4, SYNE1, and FOXE1 methylation. Functional assays were performed in SYNE1 and FOXE1 stably transfected cell lines. The sensitivity of NDRG4, GATA5, FOXE1, and SYNE1 methylation in all stages of colorectal cancer (154 cases, 444 controls) was 27% [95% confidence interval (CI), 20%-34%), 18% (95% CI, 12%-24%), 46% (95% CI, 38%-54%), and 47% (95% CI, 39%-55%), with a specificity of 95% (95% CI, 93%-97%), 99% (95% CI, 98%-100%), 93% (95% CI, 91%-95%), and 96% (95% CI, 94%-98%), respectively. Combining SYNE1 and FOXE1, increased the sensitivity to 56% (95% CI, 48%-64%), while the specificity decreased to 90% (95% CI, 87%-93%) in the training set and to 58% sensitivity (95% CI, 46%-70%) and 91% specificity (95% CI, 80%-100%) in a test set (66 cases, 240 controls). SYNE1 overexpression showed no major differences in cell proliferation, migration, and invasion compared with controls. Overexpression of FOXE1 significantly decreased the number of colonies in SW480 and HCT116 cell lines. Overall, our data suggest that SYNE1 and FOXE1 are promising markers for colorectal cancer detection. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25538088      PMCID: PMC4316751          DOI: 10.1158/1940-6207.CAPR-14-0198

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  49 in total

1.  Methylation changes in faecal DNA: a marker for colorectal cancer screening?

Authors:  Hannes M Müller; Michael Oberwalder; Heidi Fiegl; Maria Morandell; Georg Goebel; Matthias Zitt; Markus Mühlthaler; Dietmar Ofner; Raimund Margreiter; Martin Widschwendter
Journal:  Lancet       Date:  2004-04-17       Impact factor: 79.321

2.  Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool.

Authors:  Hannes M Müller; Simone Millinger; Heidi Fiegl; Georg Goebel; Lennart Ivarsson; Andreas Widschwendter; Elisabeth Müller-Holzner; Christian Marth; Martin Widschwendter
Journal:  Clin Chem       Date:  2004-11       Impact factor: 8.327

3.  Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer.

Authors:  TaeJeong Oh; Nayoung Kim; Youngho Moon; Myung Soon Kim; Benjamin D Hoehn; Chan Hee Park; Tae Soo Kim; Nam Kyu Kim; Hyun Cheol Chung; Sungwhan An
Journal:  J Mol Diagn       Date:  2013-06-07       Impact factor: 5.568

4.  Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer.

Authors:  Konstanze Lenhard; Guido T Bommer; Silke Asutay; Rolf Schauer; Thomas Brabletz; Burkhard Göke; Rolf Lamerz; Frank T Kolligs
Journal:  Clin Gastroenterol Hepatol       Date:  2005-02       Impact factor: 11.382

5.  Factors associated with colon cancer screening: the role of patient factors and physician counseling.

Authors:  Christina C Wee; Ellen P McCarthy; Russell S Phillips
Journal:  Prev Med       Date:  2004-12-29       Impact factor: 4.018

6.  Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene.

Authors:  Wei-Dong Chen; Z James Han; Joel Skoletsky; Jeff Olson; Jerome Sah; Lois Myeroff; Petra Platzer; Shilong Lu; Dawn Dawson; Joseph Willis; Theresa P Pretlow; James Lutterbaugh; Lakshmi Kasturi; James K V Willson; J Sunil Rao; Anthony Shuber; Sanford D Markowitz
Journal:  J Natl Cancer Inst       Date:  2005-08-03       Impact factor: 13.506

7.  Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front.

Authors:  T Brabletz; A Jung; K Hermann; K Günther; W Hohenberger; T Kirchner
Journal:  Pathol Res Pract       Date:  1998       Impact factor: 3.250

8.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

Authors:  J S Mandel; J H Bond; T R Church; D C Snover; G M Bradley; L M Schuman; F Ederer
Journal:  N Engl J Med       Date:  1993-05-13       Impact factor: 91.245

9.  GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer.

Authors:  Yoshimitsu Akiyama; Neil Watkins; Hiromu Suzuki; Kam-Wing Jair; Manon van Engeland; Manel Esteller; Hidekazu Sakai; Chun-Yan Ren; Yasuhito Yuasa; James G Herman; Stephen B Baylin
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

10.  Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.

Authors:  Elena Miotto; Silvia Sabbioni; Angelo Veronese; George A Calin; Sergio Gullini; Alberto Liboni; Laura Gramantieri; Luigi Bolondi; Eros Ferrazzi; Roberta Gafà; Giovanni Lanza; Massimo Negrini
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

View more
  14 in total

1.  Elevated expression of cellular SYNE1, MMP10, and GTPase1 and their regulatory role in hepatocellular carcinoma progression.

Authors:  Laila H Faraj Shaglouf; Maryam Ranjpour; Saima Wajid; Swatantra Kumar Jain
Journal:  Protoplasma       Date:  2019-08-19       Impact factor: 3.356

Review 2.  Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.

Authors:  Farah J Nassar; Zahraa S Msheik; Rihab R Nasr; Sally N Temraz
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

3.  Technical considerations in PCR-based assay design for diagnostic DNA methylation cancer biomarkers.

Authors:  Maartje Massen; Kim Lommen; Kim A D Wouters; Johan Vandersmissen; Wim van Criekinge; James G Herman; Veerle Melotte; Leo J Schouten; Manon van Engeland; Kim M Smits
Journal:  Clin Epigenetics       Date:  2022-04-27       Impact factor: 7.259

Review 4.  Methylation of cell-free circulating DNA in the diagnosis of cancer.

Authors:  Kristina Warton; Goli Samimi
Journal:  Front Mol Biosci       Date:  2015-04-22

Review 5.  Diagnostic Performance of DNA Hypermethylation Markers in Peripheral Blood for the Detection of Colorectal Cancer: A Meta-Analysis and Systematic Review.

Authors:  Bingsheng Li; Aihua Gan; Xiaolong Chen; Xinying Wang; Weifeng He; Xiaohui Zhang; Renxiang Huang; Shuzhu Zhou; Xiaoxiao Song; Angao Xu
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

6.  Aging related methylation influences the gene expression of key control genes in colorectal cancer and adenoma.

Authors:  Orsolya Galamb; Alexandra Kalmár; Barbara Kinga Barták; Árpád V Patai; Katalin Leiszter; Bálint Péterfia; Barnabás Wichmann; Gábor Valcz; Gábor Veres; Zsolt Tulassay; Béla Molnár
Journal:  World J Gastroenterol       Date:  2016-12-21       Impact factor: 5.742

7.  Hypermethylated DNA, a circulating biomarker for colorectal cancer detection.

Authors:  Simon Ladefoged Rasmussen; Henrik Bygum Krarup; Kåre Gotschalck Sunesen; Martin Berg Johansen; Mogens Tornby Stender; Inge Søkilde Pedersen; Poul Henning Madsen; Ole Thorlacius-Ussing
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

8.  Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: A meta-analysis.

Authors:  Yuzhou Zhu; Tinghan Yang; Qingbin Wu; Xuyang Yang; Jianqi Hao; Xiangbing Deng; Shuo Yang; Chaoyang Gu; Ziqiang Wang
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

Review 9.  Updates on Clinical Use of Liquid Biopsy in Colorectal Cancer Screening, Diagnosis, Follow-Up, and Treatment Guidance.

Authors:  Omayma Mazouji; Abdelhak Ouhajjou; Roberto Incitti; Hicham Mansour
Journal:  Front Cell Dev Biol       Date:  2021-05-24

10.  Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing.

Authors:  Shafina-Nadiawati Abdul; Nurul-Syakima Ab Mutalib; Khor S Sean; Saiful E Syafruddin; Muhiddin Ishak; Ismail Sagap; Luqman Mazlan; Isa M Rose; Nadiah Abu; Norfilza M Mokhtar; Rahman Jamal
Journal:  Front Pharmacol       Date:  2017-07-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.